Graf RP, et al. - In a cross-sectional cohort of 193 different individuals with progressing metastatic castration-resistant prostate cancer (mCRPC) from whom 255 samples were drawn at the time of the second-line or later treatment decision, researchers showed the clinical advantage of the nuclear-localized androgen receptor splice variant 7 (AR-V7) test for men with progressing mCRPC at the second line of therapy or greater in order to notify the choice of an androgen receptor signaling inhibitor (ARSI) or a taxane. On the basis of patient prognosis physician propensity for choosing an ARSI or taxane was measured. It was found that with regard to decisions based individually on standard-of-care measures, the use of the nuclear-localized AR-V7 circulating tumor cells test to notify treatment choice could enhance patient outcomes.